Patents by Inventor Jan Trofast

Jan Trofast has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use for budesonide and formoterol
    Patent number: 8461211
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: June 11, 2013
    Assignee: AstraZeneca AB
    Inventors: Carl-Axel Bauer, Jan Trofast
  • DRY POWDER FORMULATIONS COMPRISING ASCORBIC ACID DERIVATES
    Publication number: 20110105449
    Abstract: The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them.
    Type: Application
    Filed: November 6, 2008
    Publication date: May 5, 2011
    Applicant: ASTRAZENECA R&D
    Inventor: Jan Trofast
  • New Use For Budesonide and Formoterol
    Publication number: 20110097282
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: December 30, 2010
    Publication date: April 28, 2011
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Use for budesonide and formoterol
    Patent number: 7897646
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: March 1, 2011
    Assignee: AstraZeneca AB
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Inhaler with powder dislodging member
    Patent number: 7841340
    Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: November 30, 2010
    Assignee: AstraZeneca AB
    Inventors: Jan Andersson, Allan Dagsland, Hans Strid, Jan Trofast, Stefan Friess, Harald Heckenmueller, Uwe Rollwage, Volker Tiedemann, John Conway
  • Inhalation device
    Patent number: 7779836
    Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: August 24, 2010
    Assignee: AstraZeneca AB
    Inventors: Jan Andersson, Allan Dagsland, Hans Strid, Jan Trofast, Stefan Friess, Harald Heckenmueller, Uwe Rollwage, Volker Tiedemann, John Conway
  • INHALATION DEVICE
    Publication number: 20080092886
    Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).
    Type: Application
    Filed: November 15, 2007
    Publication date: April 24, 2008
    Inventors: Jan Andersson, Allan Dagsland, Hans Strid, Jan Trofast, Stefan Friess, Harald Heckenmueller, Uwe Rollwage, Volker Tiedemann, John Conway
  • Use for budesonide and formoterol
    Publication number: 20060189587
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: November 13, 2001
    Publication date: August 24, 2006
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Use of an H+, K+ -ATPase inhibitor in the treatment of asthma
    Publication number: 20060025450
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Application
    Filed: February 14, 2005
    Publication date: February 2, 2006
    Inventors: Per Lindberg, Joan Pinas-Masso, Jordi Serra-Carreras, Jan Trofast
  • Novel formulation
    Publication number: 20050152847
    Abstract: The present invention relates to specific excipients for powder formulations for oral and nasal inhalation.
    Type: Application
    Filed: March 3, 2003
    Publication date: July 14, 2005
    Inventors: Eva Trofast, Jan Trofast
  • Inhalation device
    Publication number: 20040065325
    Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).
    Type: Application
    Filed: September 29, 2003
    Publication date: April 8, 2004
    Applicant: AstraZeneca AB, a Swedish corporaion
    Inventors: Jan Andersson, Allan Dagsland, Hans Strid, Jan Trofast, Stefan Friess, Harald Heckenmueller, Uwe Rollwage, Volker Tiedemann, John Conway
  • Inhalation device
    Patent number: 6655380
    Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entertainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: December 2, 2003
    Assignee: Astrazeneca AB
    Inventors: Jan Andersson, Allan Dagsland, Hans Strid, Jan Trofast, Stefan Friess, Harald Heckenmueller, Uwe Rollwage, Volker Tiedemann, John Conway
  • Use of an H+, K+-ATPase inhibitor in the treatment of asthma
    Publication number: 20030216439
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Application
    Filed: June 11, 2003
    Publication date: November 20, 2003
    Inventors: Per Lindberg, Joan Pinas-Masso, Jordi Serra-Carreras, Jan Trofast
  • Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
    Patent number: 6599927
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: July 29, 2003
    Assignee: AstraZeneca AB
    Inventors: Per Lindberg, Joan Piñas-Massó, Jordi Serra-Carreras, Jan Trofast
  • Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
    Patent number: 6380222
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+,K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: April 30, 2002
    Assignee: AstraZeneca AB
    Inventors: Per Lindberg, Joan Piñas-Massó, Jordi Serra-Carreras, Jan Trofast
  • Use for budesonide and formoterol
    Publication number: 20020042404
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: November 13, 2001
    Publication date: April 11, 2002
    Applicant: Astra Aktiebolag, a Swedish Corporation
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Use of an H+, K+-ATPase inhibitor in the treatment of widal's syndrome
    Publication number: 20010029255
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Application
    Filed: April 13, 2001
    Publication date: October 11, 2001
    Inventors: Per Lindberg, Joan Pinas-Masso, Jordi Serra-Carreras, Jan Trofast
  • Formulation for inhalation
    Patent number: 6287540
    Abstract: A dry powder composition comprising one more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: September 11, 2001
    Assignee: Astra Aktiebolag
    Inventor: Jan Trofast
  • Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
    Publication number: 20010020014
    Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+,K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
    Type: Application
    Filed: April 13, 2001
    Publication date: September 6, 2001
    Inventors: Per Lindberg, Joan Pinas-Masso, Jordi Serra-Carreras, Jan Trofast
  • Process for the preparation of respirable particles
    Patent number: 6221398
    Abstract: A process for producing a pharmaceutical powder for inhalation comprising crystalline particles of an inhalation compound, comprising dissolving an inhalation compound in a solvent; and introducing the solution containing the inhalation compound in droplet form or as a jet stream into an anti-solvent which is miscible with the solvent and which is under agitation.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: April 24, 2001
    Assignee: Astra Aktiebolag
    Inventors: Edib Jakupovic, Jan Trofast